Therapeutics for Multiple Sclerosis Symptoms

被引:38
|
作者
Ben-Zacharia, Aliza Bitton [1 ]
机构
[1] Mt Sinai Sch Med, Corinne Goldsmith Dickinson Ctr Multiple Sclerosi, New York, NY USA
来源
MOUNT SINAI JOURNAL OF MEDICINE | 2011年 / 78卷 / 02期
关键词
multiple sclerosis; quality of life; rehabilitation; symptoms management; FEMALE SEXUAL DYSFUNCTION; CONTROLLED-TRIAL; PHARMACOLOGICAL MANAGEMENT; COGNITIVE IMPAIRMENT; DOUBLE-BLIND; DEPRESSION; SPASTICITY; FAMPRIDINE; FATIGUE; PAIN;
D O I
10.1002/msj.20245
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Symptoms management in multiple sclerosis is an integral part of its care. Accurate assessment and addressing the different symptoms provides increased quality of life among patients with multiple sclerosis. Multiple sclerosis symptoms may be identified as primary, secondary, or tertiary symptoms. Primary symptoms, such as weakness, sensory loss, and ataxia, are directly related to demyelination and axonal loss. Secondary symptoms, such as urinary tract infections as a result of urinary retention, are a result of the primary symptoms. Tertiary symptoms, such as reactive depression or social isolation, are a result of the social and psychological consequences of the disease. Common multiple sclerosis symptoms include fatigue and weakness; decreased balance, spasticity and gait problems; depression and cognitive issues; bladder, bowel, and sexual deficits; visual and sensory loss; and neuropathic pain. Less-common symptoms include dysarthria and dysphagia, vertigo, and tremors. Rare symptoms in multiple sclerosis include seizures, hearing loss, and paralysis. Symptom management includes nonpharmacological methods, such as rehabilitation and psychosocial support, and pharmacological methods, ie, medications and surgical procedures. The keys to symptom management are awareness, knowledge, and coordination of care. Symptoms have to be recognized and management needs to be individualized. Multiple sclerosis therapeutics include nonpharmacological strategies that consist of lifestyle modifications, rehabilitation, social support, counseling, and pharmacological agents or surgical procedures. The goal is vigilant management to improve quality of life and promote realistic expectations and hope. Mt Sinai J Med 78:176-191, 2011. (C) 2011 Mount Sinai School of Medicine
引用
收藏
页码:176 / 191
页数:16
相关论文
共 50 条
  • [1] Multiple Sclerosis Clinic and Therapeutics
    Robert, Typhaine
    [J]. ACTUALITES PHARMACEUTIQUES, 2018, 57 (573): : 8 - 8
  • [2] Multiple Sclerosis: Pathogenesis and Therapeutics
    Katsara, Maria
    Apostolopoulos, Vasso
    [J]. MEDICINAL CHEMISTRY, 2018, 14 (02) : 104 - 105
  • [3] THERAPEUTICS OF MULTIPLE-SCLEROSIS
    NOSEWORTHY, JH
    [J]. CLINICAL NEUROPHARMACOLOGY, 1991, 14 (01) : 49 - 61
  • [4] Recent developments in multiple sclerosis therapeutics
    Spain, Rebecca I.
    Cameron, Michelle H.
    Bourdette, Dennis
    [J]. BMC MEDICINE, 2009, 7
  • [5] The ups and downs of multiple sclerosis therapeutics
    Hohlfeld, R
    Wiendl, H
    [J]. ANNALS OF NEUROLOGY, 2001, 49 (03) : 281 - 284
  • [6] The New Era of Multiple Sclerosis Therapeutics
    Rohit Bakshi
    [J]. Neurotherapeutics, 2013, 10 : 1 - 1
  • [7] Multiple Sclerosis. Guide to Therapeutics
    Nunez Orozco, Lilia
    [J]. REVISTA MEXICANA DE NEUROCIENCIA, 2008, 9 (03): : 248 - 248
  • [8] Developing therapeutics for the treatment of multiple sclerosis
    Virley D.J.
    [J]. NeuroRX, 2005, 2 (4): : 638 - 649
  • [9] Recent developments in multiple sclerosis therapeutics
    Rebecca I Spain
    Michelle H Cameron
    Dennis Bourdette
    [J]. BMC Medicine, 7
  • [10] The New Era of Multiple Sclerosis Therapeutics
    Bakshi, Rohit
    [J]. NEUROTHERAPEUTICS, 2013, 10 (01) : 1 - 1